Raju Prasad is CFO at CRISPR Therapeutics AG (CRSP). They have made 7 open-market trades across 1 company since 2024, most recently 2026-08-07.
CIK 0001968317
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CRSP | 14,815 | $767K |
Shares reported on the most recent Form 4, priced at the 2026-08-11 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CRSP | SELL | 2026-03-23 | 2026-03-24 | $46.78 | $173K | +4.0% | +16.8% | +15.0% |
| CRSP | SELL | 2026-03-16 | 2026-03-17 | $48.26 | $476K | -7.2% | +13.0% | +6.7% |
| CRSP | SELL | 2026-01-22 | 2026-01-26 | $60.19 | $2.1M | -17.3% | -0.5% | -8.1% |
| CRSP | SELL | 2026-01-06 | 2026-01-08 | $60.16 | $1.8M | -3.9% | -12.7% | -9.1% |
| CRSP | SELL · 10b5-1 | 2025-12-22 | 2025-12-23 | $55.90 | $1.1M | +3.1% | +7.7% | -17.0% |
| CRSP | SELL | 2025-03-21 | 2025-03-24 | $41.23 | $181K | -23.2% | -9.3% | +7.2% |
| CRSP | SELL | 2025-03-17 | 2025-03-18 | $41.80 | $315K | -10.2% | -8.3% | +0.9% |
| CRSP | SELL | 2024-03-15 | 2024-03-18 | $72.69 | $512K | -4.1% | -21.8% | -13.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.